Effects of typical and atypical antipsychotics on human glycine transporters

Schizophrenia Research

Volumn 71, Issue 1, 2004, Pages 103-112

  Williams, Jacinta B ^a   Mallorga, Pierre J ^a   Jeffrey Conn, P ^a   Pettibone, Douglas J ^a   Sur, Cyrille ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antipsychotics; Glycine transporter; Inhibition; Schizophrenia

Indexed keywords

AMINO ACID TRANSPORTER; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORIDE ION; CHLORPROMAZINE; CLOZAPINE; CLOZAPINE N OXIDE; GLYCINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; RISPERIDONE; SARCOSINE; SODIUM ION; THIORIDAZINE;

ARTICLE; BRAIN; CHORIOCARCINOMA; CONTROLLED STUDY; GLYCEROL BLOOD LEVEL; HUMAN; HUMAN CELL; KINETICS; MEASUREMENT; METABOLITE; PRIORITY JOURNAL;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CHLORIDE CHANNELS; CHORIOCARCINOMA; CLOZAPINE; FEMALE; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HALOPERIDOL; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SCHIZOPHRENIA; SODIUM CHANNELS; SYNAPSES; UTERINE NEOPLASMS;

EID: 4444268592     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.01.013     Document Type: Article

References (58)

1. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology. 99:1989;S32-S37
2. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res. Rev. 31:2000;106-112
3. Aravagiri M., Marder S.R. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/ electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J. Pharm. Biomed. Anal. 26:2001;301-311
4. Aravagiri M., Marder S.R., Van Putten T., Marshall B.D. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J. Chromatogr., B, Biomed. Sci. Appl. 656:1994;373-381
5. Ardizzone T.D., Bradley R.J., Freeman A.M. III, Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 923:2001;82-90
6. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283:1997;226-234
7. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., Tham C.-S., Tsai C., Jia J., Ashton D., Klitenick M.A. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol. Pharmacol. 60:2001;1414-1420
8. Aubrey K.R., Vandenberg R.J. N[3-(4′-Fluorophenyl)-3(4′- phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 134:2001;1429-1436
9. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124
10. Berger A.J., Dieudonne S., Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 80:1998;3336-3340
11. Bergeron R., Meyer T.M., Coyle J.T., Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15730-15734
12. Boulton D.W., DeVane C.L., Liston H.L., Markowitz J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71:2002;163-169
13. Buck K.J., Amara S.G. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Mol. Pharmacol. 48:1995;1030-1037
14. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260
15. Centorrino F., Baldessarini R.J., Frankenburg F.R., Kando J., Volpicelli S.A., Flood J.G. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry. 153:1996;820-822
16. Chen L., Mulhauser M., Yang C.R. Glycine transporter-1 blockade potentiates NMDA mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 89:2003;691-703
17. Cohen B.M., Tsuneizumi T., Baldessarini R.J., Campbell A., Babb S.M. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology. 108:1992;338-344
18. Daly D.A., Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152:1993;61-64
19. Duncan L., Parker N., Balla A., Sershen H., Javitt D.C. Clozapine inhibits rat brain synaptosomeal glycine transport via blockade of system A transport: implication for treatment of schizophrenia. Soc. Neurosci. 2003;15. (Program 580.4)
20. Evins A.E., Fitzgerald S.M., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry. 157:2000;826-828
21. Geerlings A., Lopez-Corcuera B., Aragon C. Characterization of the interactions between the glycine transporters GLYT1 and GLYT2 and the SNARE protein syntaxin 1A. FEBS Lett. 470:2000;51-54
22. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 56:1999;21-27
23. Goff D.C., Henderson D., Evins A.E., Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry. 45:1999;512-514
24. Goff D.C., Freudenreich O., Evins A.E. Augmentation strategies in the treatment of schizophrenia. CNS Spectr. 6:2001;904-911
25. Gomeza J., Zafra F., Olivares L., Gimenez C., Aragon C. Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells. Biochim. Biophys. Acta. 1233:1995;41-46
26. Heresco-Levy U. N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade. Int. J. Neuropsychopharmacol. 3:2000;243-258
27. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry. 169:1996;610-617
28. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 56:1999;29-36
29. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236
30. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 17:1997;202-204
31. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.-M., Bark N., Park M., Lindenmayer J.-P., Suckow R., Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4:2001;385-391
32. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
33. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531
34. Kinney G.G., Sur C., Burno M., Mallorga P.J., Williams J.B., Figueroa D.J., Wittmann M., Lemaire W., Conn P.J. The GlyT1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 23:2003;7586-7591
35. Kuryatov A., Laube B., Betz H., Kuhse J. Mutational analysis of the glycine-binding site of the NMDA receptor-Structural similarity with bacterial amino acid-binding proteins. Neuron. 12:1994;1291-1300
36. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry. 39:1996;213-215
37. Leveque J.-C., Macias W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., Li X.-M., Coyle J.T., Huganir R.L., Heckers S., Konradi C. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 20:2000;4011-4020
38. 3H]-(N-[3-(4′-fluorophenyl)-3- (4′-phenylphenoxy)propyl])sarcosine. Neuropharmacology. 45:2003;585-593
39. McCoy L., Richfield E.K. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett. 213:1996;137-141
40. - neurotransmitter transporters. J. Neurochem. 71:1998;1785-1803
41. Non Y., Huang Y.Q., Ju W., Kalia L.V., Ahmadian G., Wang Y.T., Salter M.W. Glycine binding primes NMDA receptor internalization. Nature. 422:2003;302-307
42. Nunez E., Lopez-Corcuera B., Vazquez J., Gimenez C., Aragon C. Differential effects of the tricyclic antidepressant amoxapine on glycine uptake mediated by the recombinant GLYT1 and GLYT2 glycine transporter. Br. J. Pharmacol. 129:2000;200-206
43. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry. 156:1999;145-147
44. Ramamoorthy S., Leibach F.H., Mahesh V.B., Han H., Yang-Feng T., Blakely R.D., Ganapathy V. Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta. Biochem. J. 800:1994;893-900
45. Robertson G.S., Fibiger H.C. Neuropleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328
46. Smith K.E., Borden L.A., Hartig P.R., Branchek T., Weinsbank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 8:1992;927-935
47. Sur C., Betz H., Schloss P. Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1. J. Neurochem. 70:1998;2545-2553
48. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., Conn P.J. N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. 100:2003;13674-13679
49. Tokunaga H., Kudo K., Imamura T., Jitsufuchi N., Ohtsuka Y., Ikeda N. Plasma concentrations of antipychotic drugs in psychiatric inpatients. Jpn. J. Leg. Med. 51:1997;417-422
50. Tsai, G., Coyle, J., 2001. Methods for treating neuropsychiatric disorders. US patent 6,228,875 B1.
51. Tsai G., Yang P., Chung L.-C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089
52. Tsai G.E., Yang P., Chung l.-C., Tsai I.-C., Tsai C.-W., Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry. 156:1999;1822-1825
53. Tsuneizumi T., Babb S.M., Cohen B.M. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol. Psychiatry. 32:1992;817-824
54. Vandenberg R.J., Aubrey K.R. Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin. Ther. Targets. 5:2001;507-518
55. Williams J.B., Mallorga P.J., Conn P.J., Pettibone D.J., Sur C. Antagonism of glycine transporter activity by typical and atypical antipsychotics. Schizophr. Res. 60:2003;317
56. - dependent neurotransmitter transporter activity. Anal. Biochem. 321:2003;31-37
57. Yoshimura R., Yanagihara N., Hara K., Terao T., Nakamura J., Ueno S., Toyohira Y., Uezonon Y., Kaneko S., Kawamura M., Abe K., Izumi F. Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells. Psychopharmacology. 149:2000;17-23
58. Zafra F., Aragon C., Olivares L., Danbolt N.C., Gimenez C., Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J. Neurosci. 15:1995;3952-3969